KLK3 and posterior cortical atrophy: Le et al. reported the first study on the clinical utility of PHI in a prospective PCa screening study [29], in which PHI had the best overall performance (AUC: 0.770) to discriminate PCa from benign disease in men with PSA levels between 2.5 and 10 ng/mL and a negative DRE.